OCGN
Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.36
+0.74%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.4x
Market Cap
$461.19M
MomentumView details →
1D Return
+0.74%
YTD Return
−2.61%
RSI (14)
46.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.4x
Market Cap
$461.19M
RSI (14)
46.3
MomentumView details →
1D Return
+0.74%
YTD Return
−2.61%
SummaryUpdated Jun 1, 2026
Ocugen, Inc. (NASDAQ:OCGN) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Malvern, Pennsylvania. The company went public in December 2014 and has evolved from its initial focus on COVID-19 vaccines to become a specialized developer of gene therapies for inherited retinal diseases. Ocugen is currently advancing multiple clinical programs targeting various forms of blindness, with three potential biologics license applications planned for filing within the next three years.
Similar companies
Latest newsMore news →
Ocugen dosed the first patient in the global Phase 3 registrational trial of its OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration.4d agoOcugen announced plans to file Biologics License Applications (BLAs) for its gene therapy programs targeting inherited retinal diseases and dry age-related macular degeneration, with filings expected in 2027.20d agoOcugen received FDA clearance to initiate a Phase 3 trial for OCU410 in geographic atrophy and was granted RMAT designation for OCU410.30d ago